Skip to main content

Published locations for FDA issues revised warning for adverse effects associated with canagliflozin

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA issues revised warning for adverse effects associated with canagliflozin

User login

  • Reset your password
  • /content/fda-issues-revised-warning-adverse-effects-associated-canagliflozin
  • /familypracticenews/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /internalmedicinenews/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /obgynnews/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /rheumatologynews/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /clinicalendocrinologynews/article/102559/diabetes/fda-issues-revised-warning-adverse-effects
  • /obgyn/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated-canagliflozin
  • /endocrinology/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /rheumatology/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /internalmedicine/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /familymedicine/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated
  • /type-2-diabetes-icymi/article/102559/diabetes/fda-issues-revised-warning-adverse-effects-associated